TACI-Fc FUSION PROTEIN AND ITS USE Russian patent published in 2024 - IPC A61K38/17 C07K14/705 C07K19/00 A61P37/06 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the use of an optimized TACI-Fc fusion protein in a method of treating systemic lupus erythematosus (SLE) and in the production of a drug for the treatment of SLE. Treatment of SLE involves administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation of a recombinant TACI-Fc fusion protein at a dose of 80–240 mg per administration. The recombinant TACI-Fc fusion protein contains amino acids 13–118 of the TACI extracellular domain, which have the sequence represented by amino acids 1–106 in SEQ ID NO: 1, and an Fc fragment having the sequence represented by amino acids 107–333 in SEQ ID NO: 1. Two recombinant TACI-Fc fusion proteins form a double-stranded structure through an interchain disulfide bond formed at the Fc hinge region.

EFFECT: reduction of the adverse reactions experienced by patients during treatment for SLE, the absence of serious safety risks, and restoration of the ability of conceiving and child-bearing in some patients as a result of treatment.

12 cl, 2 dwg, 7 tbl, 3 ex